Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Alto Neuroscience (NYSE:ANRO) but lowers the price target from $32 to $10.
October 23, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Brian Skorney continues to rate Alto Neuroscience as Outperform, but significantly reduces the price target from $32 to $10, indicating a reassessment of the company's valuation.
The reduction in price target from $32 to $10 suggests a significant change in the analyst's valuation of Alto Neuroscience, which could lead to a negative short-term impact on the stock price despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100